Given the safety and tolerability profiles of currently available biologics and small-molecule oral agents for plaque psoriasis, there is a need for novel, better-tolerated therapies. Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor that binds to the regulatory or pseudokinase domain of TYK2 and allosterically inhibits the enzyme from initiating cytokine synthesis and plaque psoriasis pathogenesis. 

Here, we summarize the results of POETYK-PSO-2, a phase III, randomized, double-blind study assessing the efficacy and safety of deucravacitinib against apremilast and placebo for the treatment of moderate-to-severe plaque psoriasis (NCT03611751),¹ published in the Journal of the American Academy of Dermatology by Strober et al.

Methods¹

• POETYK PSO-2 trial was a 52-week, double-blinded, phase III study conducted across 191 sites in 16 countries between June 2018 and November 2019, and included 1,020 adult patients with moderate-to-severe plaque psoriasis and:

• • Psoriasis Area and Severity Index (PASI) ≥12; 
  • static Physician’s Global Assessment (sPGA) ≥3; and 
  • body surface area involvement ≥10% for ≥6 months.

• Patients were randomized to deucravacitinib 6 mg every day (n = 511), placebo (n = 255), or apremilast 30 mg twice a day (n = 254).

• The coprimary efficacy endpoints at Week 16, for patients treated with deucravacitinib vs placebo, were:

• • ≥75% reduction from baseline in PASI (PASI 75); and 
  • sPGA score of 0 (clear) or 1 (almost clear), with a ≥2-point improvement from baseline (sPGA 0/1). 

• Secondary endpoints included Week 16 PASI 90, PASI 100, sPGA 0 vs placebo, and Week 24 PASI 90 vs apremilast.

Key findings¹

• More patients who received deucravacitinib achieved the coprimary endpoints of PASI 75 and sPGA 0/1 at Week 16 than patients who received apremilast or placebo (Figure 1).
• Deucravacitinib was also associated with higher PASI 90, PASI 100, and sPGA 0 responses at Week 16 and a higher PASI 90 vs apremilast at Week 24.
• Rates of adverse events (AEs) and serious AEs were similar in patients who received deucravacitinib and those who received apremilast; the most common AEs were nasopharyngitis and upper respiratory tract infections in the deucravacitinib group, and headache, diarrhea and nausea in the apremilast group. 

Figure 1. Efficacy measures at the end of Week 16* 

BID, twice daily; PASI, Psoriasis Area and Severity Index; QD, once daily; sPGA, static Physician’s Global Assessment.
*Data from Strober, et al.